Wilex AG | Balance Sheet

Fiscal year is December-November. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
8,920.00
2,202.00
1,306.00
4,574.00
30,381.10
19,440.40
Total Accounts Receivable
397.00
444.00
462.00
184.00
494.40
614.70
Inventories
137.00
234.00
290.00
190.00
178.00
177.60
Other Current Assets
53.00
30.00
11.00
42.00
154.90
56
Total Current Assets
9,507.00
2,910.00
2,069.00
4,990.00
31,208.40
20,288.60
Net Property, Plant & Equipment
1,324.00
1,053.00
985.00
1,267.00
1,299.60
1,949.90
Total Investments and Advances
-
157.00
29.00
26.00
46.30
36.30
Long-Term Note Receivable
2,130.00
1,850.00
36.00
5.00
5.00
5
Intangible Assets
9,182.00
9,060.00
8,978.00
8,953.00
8,930.40
8,912.10
Other Assets
169.00
-
5.00
-
-
-
Total Assets
22,312.00
15,030.00
12,102.00
15,241.00
41,489.80
31,192
ST Debt & Current Portion LT Debt
2,729.00
77.00
-
3,748.00
-
Accounts Payable
191.00
277.00
279.00
132.00
1,501.10
Other Current Liabilities
4,365.00
2,797.00
2,338.00
1,598.00
2,956.10
Total Current Liabilities
7,285.00
3,151.00
2,617.00
5,478.00
4,457.20
Long-Term Debt
25.00
-
-
-
-
Provision for Risks & Charges
52.00
3.00
5.00
7.00
8.80
Total Liabilities
7,362.00
3,154.00
2,622.00
5,485.00
4,466.00
Common Equity (Total)
14,950.00
11,876.00
9,480.00
9,756.00
37,023.90
Total Shareholders' Equity
14,950.00
11,876.00
9,480.00
9,756.00
37,023.90
Total Equity
14,950.00
11,876.00
9,480.00
9,756.00
37,023.90
Liabilities & Shareholders' Equity
22,312.00
15,030.00
12,102.00
15,241.00
41,489.80

About Wilex

View Profile
Address
Schriesheimer Strasse 101
Ladenburg Baden Wuerttemberg 68526
Germany
Employees -
Website http://heidelberg-pharma.com
Updated 07/08/2019
Heidelberg Pharma AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer. It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx), andTherapeutics (Rx). The Customer Specific Research segment includes preclinical and Antibody Drug Conjugate technology services.